By a News Reporter-Staff News Editor at Blood Weekly -- Fresh data on Oncology are presented in a new report. According to news reporting originating from Santo Andre, Brazil, by NewsRx correspondents, research stated, "The aim of this study was to evaluate the diagnostic and potential prognostic value of cell-free plasma DNA (CF-pDNA) in patients with suspected or histologically proven prostate cancer (PCa). We included 133 men with a diagnosis of PCa and 33 controls."
Our news editors obtained a quote from the research from the Department of Oncology, "PCa patients had blood samples prospectively drawn every 3 months for 2 years. CF-pDNA was measured by spectrophotometry. Considering a cut-off value of 140 ng/mL of CF-pDNA the area under the curve was of 0.824(0.757-0.879 with a sensitivity = 66.2 % and a specificity = 87.9 %) and the positive and negative likelihood ratio were of 5.46 and 0.39, respectively. CF-pDNA tends to decrease slightly and return to baseline values in about a week after biopsy. There was no statistical significant correlation between CF-pDNA levels at study entry with PSA, Gleason score, stage and biochemical recurrence free survival (BRFS). However, with a mean follow-up of 13.5 months, we could observe a significant shorter BRFS for patients with at least one value above 140 ng/mL of CF-pDNA during follow-up (p = 0.048)."
According to the news editors, the research concluded: "CF-pDNA is a potentially valuable biomarker for PCa diagnosis and a potential tool for the follow-up of patients with PCa."
For more information on this research see: Cell-free plasma DNA as biochemical biomarker for the diagnosis and follow-up of prostate cancer patients. Tumor Biology, 2013;34(5):2921-2927. Tumor Biology can be contacted at: Springer, Van Godewijckstraat 30, 3311 Gz Dordrecht, Netherlands. (Springer - www.springer.com; Tumor Biology - www.springerlink.com/content/1010-4283/)
The news editors report that additional information may be obtained by contacting M.L. Wroclawski, ABC Med Sch, Dept. of Oncol, Santo Andre, Brazil. Additional authors for this research include A. Serpa-Neto, F.L.A. Fonseca, O. Castro-Neves-Neto, A. Pompeo, M.T. Machado, A.C.L. Pompeo and A. del Giglio (see also Oncology).
Keywords for this news article include: Blood, Brazil, Oncology, Santo Andre, Biochemical, Biochemistry, DNA Research, South America, Prostate Cancer, Prostatic Neoplasms
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .